ライフサイエンスコーパス: macitentan

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e voice/web response system, to receive oral macitentan (10 mg once a day) or placebo.

2 zed (1:1:1) to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily a

3 ndomly assigned to treatment (40 patients to macitentan, 40 patients to placebo).

4 sought to investigate the effects of chronic macitentan, a dual ET-A/ET-B receptor antagonist, on car

5 We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, u

6 Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interest

7 tes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blocker.

8 The combination of macitentan and cisplatinum resulted in the potentiation

9 macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.

10 hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan a

11 ion of the cytotoxic effect, indicating that macitentan can enhance sensitivity to chemotherapy.

12 Macitentan caused LV hypertrophy regression independent

13 In vitro studies showed that macitentan decreased the aldosterone-induced cardiomyocy

14 Although macitentan did not modulate diastolic dysfunction in HFp

15 tive ischemic digital ulcers, treatment with macitentan did not reduce new digital ulcers over 16 wee

16 P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5%

17 The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5%

18 andomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.

19 e 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.

20 These results do not support the use of macitentan for the treatment of digital ulcers in this p

21 r of new digital ulcers was 1.44 in the 3-mg macitentan group (n = 88) and 1.46 in the 10-mg macitent

22 itentan group (n = 88) and 1.46 in the 10-mg macitentan group (n = 88) compared with 1.21 in the plac

23 r patient over 16 weeks was 0.94 in the 3-mg macitentan group (n = 95) and 1.08 in the 10-mg macitent

24 itentan group (n = 95) and 1.08 in the 10-mg macitentan group (n = 97) compared with 0.85 in the plac

25 an PVR decreased to 73.0% of baseline in the macitentan group and to 87.2% in the placebo group (geom

26 The most common adverse events in the macitentan group were peripheral oedema (9 [23%] of 40 p

27 Moreover, macitentan improved adverse cardiac remodeling, by reduc

28 d, placebo-controlled MERIT-1 trial assessed macitentan in 80 patients with CTEPH adjudicated as inop

29 a solid rationale for clinical evaluation of macitentan in combination with chemotherapy to overcome

30 Macitentan is beneficial for long-term treatment of pulm

31 n ET receptor antagonist, either bosentan or macitentan, markedly attenuated PD-induced MMT, fibrosis

32 The effect of macitentan on this end point was observed regardless of

33 e oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily and stratified accordi

34 treatment with the dual ETAR/ETBR antagonist macitentan prevented core complex formation and restored

35 INTERPRETATION: In MERIT-1, macitentan significantly improved PVR in patients with i

36 Macitentan significantly reduced morbidity and mortality

37 verse events more frequently associated with macitentan than with placebo were headache, nasopharyngi

38 verse events more frequently associated with macitentan than with placebo were headache, peripheral e

39 In vivo macitentan treatment reduced tumor growth, vascularizati

40 ce, 0.09 [95% CI, -0.37 to 0.54] for 3 mg of macitentan vs placebo and 0.23 [-0.27 to 0.72] for 10 mg

41 ce, 0.23 [95% CI, -0.35 to 0.82] for 3 mg of macitentan vs placebo and 0.25 [95% CI, -0.34 to 0.84] f

42 nd 0.25 [95% CI, -0.34 to 0.84] for 10 mg of macitentan vs placebo).

43 lacebo and 0.23 [-0.27 to 0.72] for 10 mg of macitentan vs placebo).

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。